Processing

Please wait...

Settings

Settings

Goto Application

1. WO2009004822 - ANTI-Muc17 ANTIBODY

Publication Number WO/2009/004822
Publication Date 08.01.2009
International Application No. PCT/JP2008/001777
International Filing Date 03.07.2008
IPC
C07K 16/18 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
C12N 15/09 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/3092
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
3076against structure-related tumour-associated moieties
3092against tumour-associated mucins
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/41
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
40characterized by post-translational modification
41Glycosylation, sialylation, or fucosylation
C07K 2317/732
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
732Antibody-dependent cellular cytotoxicity [ADCC]
Applicants
  • 株式会社未来創薬研究所 Forerunner Pharma Research Co., Ltd. [JP]/[JP] (AllExceptUS)
  • 中野清孝 NAKANO, Kiyotaka [JP]/[JP] (UsOnly)
Inventors
  • 中野清孝 NAKANO, Kiyotaka
Agents
  • 大野聖二 OHNO, Seiji
Priority Data
2007-17631904.07.2007JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) ANTI-Muc17 ANTIBODY
(FR) ANTICORPS ANTI-Muc17
(JA) 抗Muc17抗体
Abstract
(EN)
Disclosed is an antibody capable of binding to Mucin-17 (Muc17). Preferably, the antibody can bind to a peptide depicted in SEQ ID NO:3 but cannot bind to peptides depicted in SEQ ID NO:4 and SEQ ID NO:5. Also disclosed is an anti-cancer agent, preferably an anti-cancer agent against pancreatic cancer, which comprises the antibody. Further disclosed is a method for the diagnosis of cancer, which is characterized by using the antibody, preferably the antibody which cannot bind to secreted Muc17.
(FR)
L'invention concerne un anticorps capable de se lier à la mucine 17(Muc17). De préférence l'anticorps peut se lier à un peptide présenté dans SEQ ID NO:3, mais ne peut se lier à des peptides présentés dans SEQ ID NO:4 et SEQ ID NO:5. Elle concerne également un agent anticancéreux, de préférence un agent anticancéreux contre le cancer du pancréas, qui comprend l'anticorps. Elle concerne en outre un procédé pour le diagnostic du cancer, qui se caractérise par l'utilisation de l'anticorps qui ne peut se lier à Muc17 sécrété.
(JA)
 Mucin 17(Muc17)に結合する抗体が開示される。好ましくは、本発明の抗体は、配列番号3のペプチドに結合し、かつ配列番号4のペプチドおよび配列番号5のペプチドには結合しない。本発明の抗体を含む抗癌剤、好ましくは膵臓癌に対する抗癌剤、ならびに本発明の抗体、好ましくは、分泌型Muc17に結合しない抗体を用いることを特徴とする癌の診断方法も開示される。
Latest bibliographic data on file with the International Bureau